Case Report: IL2RA (CD25) deficiency: first reported cases in Morocco

CD25, the α-chain of the interleukin-2 receptor (IL2RA), is a key component of the IL-2 pathway and is essential for the development and stability of regulatory T cells. Loss-of-function variants in IL2RA cause a very rare autosomal recessive disorder marked by early-onset autoimmunity and recurrent infections with an IPEX-like presentation. We report the first two molecularly confirmed cases of IL2RA (CD25) deficiency in Morocco, each carrying a distinct homozygous mutation. Both patients were born to first-cousin parents and presented in early childhood with recurrent respiratory and gastrointestinal infections, severe failure to thrive, chronic diarrhea with celiac-like enteropathy, and autoimmune manifestations including autoimmune hepatitis, dermatitis, and, in one case, autoimmune thyroiditis. Lymphocyte subset counts and immunoglobulin levels were within or above age-appropriate ranges, but flow cytometry showed a complete absence of CD25 expression on CD4⁺ T cells in both children, whereas relatives displayed intermediate levels compatible with carrier status. Targeted next-generation sequencing identified two novel IL2RA variants: a splice-site mutation (c.65-2A>G) and a multi-exon deletion (c.557_795-1625del), both leading to loss of functional CD25. Both variants were absent from population databases and classified as likely pathogenic or pathogenic according to ACMG criteria. These two cases expand the mutational and geographic spectrum of IL2RA deficiency and highlight the importance of considering this diagnosis in infants from consanguineous families who present with unexplained polyautoimmunity and recurrent infections. Simple flow cytometric assessment of CD25 on T cells is a valuable screening tool, and early genetic confirmation is crucial to guide timely hematopoietic stem cell transplantation and genetic counselling.

1 Introduction

Interleukin-2 (IL-2) is a central cytokine in adaptive immunity, essential for T-cell activation, proliferation, and the maintenance of immune homeostasis (1, 2). IL-2 signaling is mediated through the interleukin-2 receptor (IL-2R) complex, which is composed of three subunits: IL-2Rα (CD25), IL-2Rβ (CD122), and the common γ chain (CD132) (3). The IL-2Rβ and γc subunits are responsible for signal transduction and are shared with other cytokine receptors, including those for IL-4, IL-7, IL-9, IL-15, and IL-21 (4). In contrast, IL-2Rα (CD25) is unique to the IL-2 receptor complex and has no signaling capability on its own. Its principal function is to enhance receptor affinity for IL-2, allowing efficient ligand capture even at low cytokine concentrations (5). In conventional T lymphocytes, CD25 expression is transiently induced upon activation and generally remains of low intensity, in contrast to the constitutive and high-level expression observed on regulatory T lymphocytes (Tregs), where it plays a pivotal role in mediating IL-2-driven STAT5 activation. This signaling is essential for the development, stability, and function of Tregs, and thereby critical for maintaining self-tolerance and immune homeostasis (5, 6). Although the impact of CD25 deficiency has been predominantly described in T lymphocytes, accumulating evidence indicates that certain NK cell populations particularly the CD56^bright subset constitutively express CD25 and can assemble a high-affinity IL-2 receptor, enabling them to respond to low concentrations of IL-2. For instance, Caldirola et al. reported impaired NK cell maturation and function in a patient carrying an IL2RA mutation, highlighting the importance of the IL-2/CD25 axis in NK cell biology (7). In addition, Hirakawa et al. demonstrated that CD56^bright NK cells are activated in response to low-dose IL-2 through high-affinity IL-2 receptors, further supporting the contribution of CD25 to NK cell IL-2 sensitivity (8).

CD25 deficiency is a very rare autosomal recessive monogenic immunodeficiency marked by profound immune dysregulation (9). Clinical manifestations usually begin in early infancy, with patients presenting with recurrent bacterial, viral, and fungal infections, failure to thrive, and autoimmune manifestations such as enteropathy, cytopenias, eczema, and endocrinopathies (10–18). The first human case was reported in 1997 and involved a child with severe T-cell dysfunction and diffuse lymphocytic organ infiltration (10). A decade later, it was shown that CD25 deficiency can mimic IPEX (Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked) syndrome, even in the absence of FOXP3 mutations (11). In such cases, defective IL-10 production by CD4⁺ T cells illustrates the failure of immune regulation (11).

Over the past two decades, fewer than twenty patients with IL2RA mutations have been reported worldwide (10–18). These cases confirmed that loss of CD25 expression results in defective IL-2 signaling and a breakdown of peripheral immune tolerance. Moreover, beyond these rare loss-of-function cases, common IL2RA polymorphisms have been linked to susceptibility to several autoimmune diseases in the general population, including type 1 diabetes, multiple sclerosis, and juvenile idiopathic arthritis (19–23). Such observations underscore the broader importance of the IL-2/CD25 axis in immune regulation.

Here we present the first two confirmed cases of IL2RA (CD25) deficiency in Morocco. We describe their clinical phenotypes, immunological profiles, and the discovery of two novel biallelic IL2RA mutations. To our knowledge, no molecularly confirmed cases of CD25 deficiency have previously been reported from Morocco or North Africa. These findings expand the known genotypic spectrum of IL2RA mutations and reinforce the diagnostic importance of CD25 staining by flow cytometry in patients with IPEX-like syndromes (Figure 1). Given the high rate of consanguinity in the region and the availability of curative hematopoietic stem cell transplantation, early recognition of this rare but life-threatening disorder is crucial.

Figure 1

Figure 1. Diagnostic approach to IPEX-like syndromes.

2 Methods

2.1 Patients and clinical evaluation

The two patients described in this study were evaluated and followed at the Department of Pediatric Infectious Diseases and Clinical Immunology, Mother-Child Hospital Abderrahim El Harouchi, University Hospital Ibn Rochd, Casablanca, Morocco. Detailed clinical assessments were performed, including medical history, physical examination, and relevant laboratory. Family pedigrees were obtained through direct interviews with parents.

2.2 Immunophenotyping by flow cytometry

CD25 surface expression on CD4⁺ T cells was assessed by flow cytometry. Peripheral whole blood samples were collected in EDTA tubes and processed within 24 hours. Red blood cells were lysed using an ammonium chloride-based lysing buffer. Leukocytes were stained with fluorochrome-conjugated monoclonal antibodies, including anti-CD45-V500, anti-CD3-PerCP-Cy5.5, anti-CD4-V450, and anti-CD25-PE (BD Biosciences). After incubation, samples were acquired on a FACSLyric™ flow cytometer (BD Biosciences). Standard lymphocyte subset analysis was also performed using panels of monoclonal antibodies targeting CD3, CD4, CD8, CD19, and CD16/56. Results were interpreted using age-matched reference ranges.

2.3 Genetic analysis

Genomic DNA was extracted from peripheral blood leukocytes of the patients. Targeted next-generation sequencing (NGS) was performed using a custom gene panel encompassing known primary immunodeficiency genes (including IL2RA). Sequencing libraries were prepared by hybridization capture and sequenced on an Illumina platform. Sequence reads were aligned to the human reference genome (GRCh37) and variants were called and annotated following standard guidelines of the Human Genome Variation Society (HGVS). The population frequency of each candidate variant was checked using the GeneBe platform (https://genebe.net/). In silico prediction tools were employed to evaluate variant pathogenicity: for the splice-site mutation, we used splice site prediction algorithms (ADA and RF score from dbscSNV, among others) to assess impact on splicing; for both variants, we used a deleteriousness meta-score (BayesDel) and Combined Annotation Dependent Depletion (CADD) scoring to gauge the likelihood of pathogenic effect. The variants were interpreted according to ACMG criteria. Additionally, we utilized the PopViz (https://hgidsoft.rockefeller.edu/PopViz/) and Ensembl (https://www.ensembl.org/) databases to visualize the position of the mutations in the context of variant deleteriousness and population frequency.

2.4 Ethical considerations

The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from the legal guardians of both patients for clinical investigations, genetic testing, and the publication of anonymized data. Ethical approval was granted by the Ethics Committee of the Faculty of Medicine and Pharmacy, Hassan II University of Casablanca (approval number 06/2023).

3 Results

3.1 Clinical presentation

3.1.1 Case 1 (patient 1)

The first patient was a 3-year-old girl born to first-degree consanguineous parents (Figure 2A). She was admitted to our unit for febrile respiratory distress, with a history of recurrent infections and failure to thrive. Since the age of 12 months, she had experienced frequent febrile episodes (about three per month), two to three diarrheal episodes per month, and repeated respiratory tract infections, including several pneumonias requiring hospitalization. Her medical history was also marked by refractory anemia and hepatobiliary involvement with episodes of cholestatic jaundice. At 3 years of age, she developed autoimmune gastrointestinal and hepatic manifestations: endoscopy performed for persistent abdominal symptoms revealed petechial gastritis with fold hypertrophy, and anti–tissue transglutaminase antibodies were strongly positive, confirming celiac disease (autoimmune enteropathy). She was also diagnosed with autoimmune hepatitis. A skin biopsy performed for chronic dermatitis showed features consistent with eczema. On examination, she had hepatomegaly, splenomegaly, and generalized lymphadenopathy (Table 1).

Figure 2

Figure 2. (A) Pedigrees of two unrelated Moroccan families with autosomal recessive IL2RA deficiency. Case 1 and Case 2 were both born to first-degree consanguineous parents. Affected individuals (black-filled symbols) are homozygous for distinct IL2RA mutations: c.65-2A>G in Family 1 and c.557_795-1625del in Family 2. The diagonally slashed square indicates a deceased sibling with a similar clinical phenotype, though not genetically tested. Parents are presumed heterozygous carriers (WT/M)?. Individuals labeled E? have unknown genetic status. WT: wild-type allele; M: mutant allele. Squares denote males; circles denote females. Double horizontal lines represent consanguineous unions. (B) Schematic representation of the IL-2Rα (CD25) protein structure with corresponding exon organization, showing the location of the mutations identified in our patients (highlighted in red) relative to previously reported IL2RA mutations (shown in black). The red horizontal bar indicates the multi-exon genomic deletion spanning exons 4–7 identified in Patient 2.

Table 1

Table 1. Clinical characteristics of the two Moroccan patients with IL-2Rα deficiency.

Laboratory investigations demonstrated moderate microcytic anemia (hemoglobin 9.3 g/dL; MCV 76.8 fL) and mild leukocytosis (10.98×10³/µL) with neutrophils 4.60×10³/µL and lymphocytes 4.86×10³/µL (Table 2). Platelets were slightly elevated (409×10³/µL). HIV serology was negative. Lymphocyte subset immunophenotyping revealed normal absolute T-, B-, and NK-cell counts for her age: CD3⁺ 3103/µL, CD4⁺ 1861/µL, CD8⁺ 881/µL, CD19⁺ 1221/µL, and CD16⁺/CD56⁺ 308/µL. Serum immunoglobulin testing showed marked hypergammaglobulinemia (IgG 33.56 g/L), while IgA (2.47 g/L), IgM (0.52 g/L), and IgE (50 IU/mL) were within normal ranges (Table 2).

Table 2

Table 2. Laboratory and immunological findings of two Moroccan patients with IL-2Rα deficiency.

The patient is currently receiving monthly intravenous immunoglobulin replacement therapy, along with antibacterial prophylaxis. She is maintained on a gluten-free diet and immunosuppressive treatment. Despite this management, she continues to experience intermittent episodes of lymphoproliferation, characterized by transient peripheral lymphadenopathy.

3.1.2 Case 2 (patient 2)

The second patient was an 8-year-old girl, also born to first-cousin parents from a different family (Figure 2A). Her symptoms began in early infancy (Table 1). At 4 months of age, she was hospitalized for persistent unexplained fever, and by 5 months she had developed chronic diarrhea. Throughout infancy, she exhibited pronounced growth retardation and delayed motor development. At 2 years, evaluation for persistent diarrhea and failure to thrive revealed malabsorption with villous atrophy on intestinal biopsy. This was initially managed as celiac disease; her anti-transglutaminase antibody titers were exceedingly high (>300 IU/mL). Despite a gluten-free diet, her gastrointestinal symptoms persisted, raising suspicion of a more complex autoimmune enteropathy. She also had refractory iron-deficiency anemia, hepatosplenomegaly, and persistent lymphadenopathy. A liver biopsy performed due to prolonged hepatomegaly showed evidence of steatohepatitis. Around the age of 3, she developed signs of thyroid autoimmunity: cervical ultrasound revealed features of chronic thyroiditis, and she presented with anterior neck swelling. Thyroid function tests confirmed primary hypothyroidism (free T4 ~0.5 µg/dL, TSH >100 µIU/mL) with markedly elevated anti-thyroperoxidase antibodies (>600 IU/mL), consistent with autoimmune thyroiditis. She was started on thyroxine replacement therapy. She also had recurrent episodes of wheezing and dyspnea and chronic xerotic dermatitis with eczema-like features. Taken together, her clinical picture was consistent with early-onset immune dysregulation resembling an IPEX-like phenotype.

On examination, she had stunted growth and signs of chronic systemic illness. Laboratory testing revealed severe microcytic hypochromic anemia (hemoglobin 4.3 g/dL), leukocytosis (17.0×10³/µL), marked absolute lymphocytosis (13.35×10³/µL), and relative neutropenia (2.10×10³/µL). Platelets were elevated (443×10³/µL). HIV serology was negative. Lymphocyte subset immunophenotyping showed normal B-cell counts, CD19⁺ 605/µL, whereas T and NK cells were increased for her age: CD3⁺ 3632/µL, CD4⁺ 1917/µL, CD8⁺ 1564/µL and CD16⁺/CD56⁺ 706/µL (Table 2). Serum immunoglobulin testing showed marked hypergammaglobulinemia (IgG 21, 02 g/L). The other immunoglobulins were also within age-appropriate ranges (IgA ~0.7 g/L; IgM ~1.0 g/L). The therapeutic management was based on monthly intravenous immunoglobulin replacement therapy, combined with antibacterial prophylaxis, a gluten-free diet, and immunosuppressive treatment. Thyroid hormone replacement therapy with levothyroxine (4 mg/kg/day) was initiated. To date, the clinical course is characterized by stabilization of clinical manifestations. Her family history was notable for a deceased older brother who died at 4½ years after a similar clinical course characterized by recurrent respiratory infections, severe growth failure, autoimmune hepatitis, and enteropathy (Figure 2A). Although no genetic testing was performed at the time, his presentation strongly suggests he may have been affected by the same underlying immunological disorder.

3.2 CD25 surface expression

Given the autoimmune manifestations and lymphoproliferation observed in both cases, immunophenotyping focused on CD25 expression. Flow cytometric analysis of whole blood lymphocytes showed a complete absence of CD25 expression on CD4⁺ T cells in both patients. In healthy controls, approximately 20–30% of circulating CD4⁺ T cells express CD25. In Case 1, only 0.16% of CD4⁺ T cells expressed CD25, and in Case 2 the proportion was 0.00%, confirming a total lack of detectable CD25 on the cell surface (Figure 2). In contrast, the parents from both families displayed intermediate CD25 expression, with levels ranging from 9–15% of CD4⁺ T cells, clearly reduced compared with controls but higher than in the affected children, consistent with a heterozygous carrier status (Figure 3).

Figure 3

Figure 3. Flow cytometry analysis of CD25 expression on CD4⁺ T cells in patients and family members. Flow cytometric analysis of CD25 (IL-2Rα) expression on CD4⁺ T cells in Case 1 and Case 2, their relatives, and a healthy control. (A) Case 1: CD25⁺CD4⁺ T cells were nearly absent in the patient (0.16%) compared to a healthy control (29.52%). Both parents showed reduced CD25 expression (father: 10.83%; mother: 15.77%), consistent with presumed heterozygous carrier status. (B) Case 2: CD25⁺CD4⁺ T cells were undetectable in the patient (0.00%). Her sister and parents displayed intermediate CD25 expression levels (sister: 9.14%; father: 11.20%; mother: 13.82%), also supporting heterozygous status.

3.3 Genetic findings

Based on the absent CD25 expression, genetic analysis of IL2RA was performed. Targeted next-generation sequencing (NGS) of a primary immunodeficiency gene panel identified homozygous IL2RA variants in both patients, consistent with an autosomal recessive defect of the IL-2 receptor α chain (CD25). No additional variants clearly compatible with the clinical phenotype were detected in other genes on the panel.

In Case 1, NGS revealed a homozygous splice-site variant in IL2RA, NM_000417.3: c.65-2A>G, located at the invariant acceptor site of intron 2, immediately upstream of exon 3 (Figure 2B). This change affects the canonical 3′ splice acceptor site and is predicted to abolish normal splicing of exon 3. The variant was absent from population databases (including gnomAD) and was not listed in ClinVar or other publicly available disease variant repositories at the time of analysis, indicating that it is extremely rare and previously unreported. In silico prediction tools uniformly supported a deleterious effect: the variant showed a high CADD score (34), a BayesDel_addAF score of 0.56, and splice-site prediction scores from dbscSNV (ADA = 1.00; RF = 0.93), together with an elevated Eigen score (0.85) (Supplementary Table 1). In PopViz, c.65-2A>G clustered among variants with high predicted deleteriousness and very low minor allele frequency (Figure 4). On the basis of these data, and given that loss-of-function of IL2RA is a known mechanism of disease, this variant was classified as likely pathogenic according to ACMG criteria (PVS1, PM2, PP3).

Figure 4

Figure 4. CADD vs. MAF plot of CD25 by PopViz. The vertical and horizontal axes show the combined annotation-dependent depletion (CADD) and the minor allele frequency (MAF) scores, respectively. The red dot is the c.65-2A>G variant and the other dots are the other variants. The log₈₁ MAF is −6 and the CADD score is 34, which indicates that the new mutation c.65-2A>G is probably deleterious.

For Case 2, NGS read-depth analysis identified a homozygous multi-exon deletion in IL2RA, corresponding at the cDNA level to c.557_795-1625del. This deletion encompasses the 3′ part of exon 4 and all of exons 5–7, removing a substantial portion of the coding sequence that includes the Extracellular domain and transmembrane domains of CD25 (Figure 2B). Such a structural alteration is expected to produce a truncated, non-functional protein or lead to degradation of the transcript through nonsense-mediated decay, and therefore represents a clear loss-of-function allele. The deletion was not found in population databases and, to our knowledge, has not been previously reported. Because this is a large exon-level deletion, standard single-nucleotide in silico prediction scores (such as CADD or BayesDel) are not applicable; pathogenicity was therefore assessed on the basis of the predicted protein truncation, the essential domains affected, and its absence from controls. According to ACMG criteria, this variant was classified as pathogenic (PVS1, PM2).

Taken together with the complete absence of CD25 expression on CD4⁺ T cells and the IPEX-like clinical presentation, the identified biallelic IL2RA variants establish the diagnosis of IL-2Rα (CD25) deficiency in both affected children.

4 Discussion

We report two pediatric cases of complete IL-2Rα (CD25) deficiency, each caused by novel homozygous mutations, representing the first documented patients from Morocco and, to our knowledge, the North African region. These patients underscore key features of this syndrome and have implications for diagnosis and management in our context. CD25 deficiency results in a distinctive immunological phenotype that combines features of immunodeficiency with severe autoimmunity (10–18). Due to the absence of CD25, IL-2 signaling through the IL-2R is virtually absent in patient T cells, especially affecting regulatory T cells that require IL-2 for survival and function. As a consequence, patients are unable to maintain normal immune tolerance, leading to multi-organ autoimmunity, such as enteropathy, endocrinopathies, dermatitis, and cytopenias, early in life (12–14). At the same time, IL-2 is critical for effective immune responses; thus these patients also experience vulnerability to infections despite having normal or even expanded T-cell numbers (15, 16). The combination of recurrent infections (often opportunistic or chronic viral infections) with IPEX-like autoimmune disease is a hallmark of CD25 deficiency (17). Both of our patients exhibited this combination, with persistent viral infections and severe chronic diarrhea and endocrine autoimmunity akin to IPEX syndrome. Indeed, CD25 deficiency has been described as an “IPEX-like” disorder in the literature (11), since the clinical presentation overlaps considerably with FOXP3-deficient IPEX, apart from the inheritance pattern (CD25 deficiency is autosomal recessive, affecting both genders equally, unlike X-linked IPEX). One distinguishing feature observed in prior CD25-deficient cases is extensive lymphoproliferation – for example, Sharfe et al. noted lymphocytic infiltrates in lung, liver, gut, and other tissues of their patient (10). Our patients also had significant hepatosplenomegaly and lymph node enlargement, consistent with lymphoproliferation. The immunopathology likely reflects uncontrolled activation and expansion of autoreactive T cells that lack regulation by Tregs (11, 12). In line with previous reports, we found that both patients had no detectable CD25 on their T cells, confirming the diagnosis at a protein level. This was also true in all other published cases of IL2RA mutations. To date, all reported patients showed absent CD25 expression on flow cytometry (Table 3) (10–18). This immunophenotypic hallmark can be invaluable for diagnosis: in an infant or young child with unexplained polyautoimmunity and infections, flow cytometric analysis of CD25 on T cells can provide an immediate clue to IL2RA deficiency, even before genetic results are available.

Table 3

Table 3. Reported cases of CD25 deficiency: a comparative genotype-phenotype summary.

The genetic findings in our patients expand the known mutational spectrum of IL2RA. Prior to this report, approximately 15 cases from various ethnic backgrounds had been documented in the literature (10–18). The majority of reported mutations are either missense substitutions that disrupt protein expression/folding or nonsense/frameshift mutations leading to truncated proteins (10–15, 17). For example, Sharfe et al. reported a frameshift (4-bp deletion) in IL2RA that produced a nonfunctional receptor (10). Vignoli et al. described a conformational missense mutation that prevented IL-2Rα from reaching the cell surface (17). Our Case 1 has a splice-site mutation (c.65-2A>G) which is predicted to cause abnormal mRNA splicing and likely results in an out-of-frame transcript or nonsense-mediated decay. Notably, this splice mutation is novel and had not been recorded in any variant databases, emphasizing the uniqueness of each family’s mutation in this ultra-rare disease. Our Case 2 harbors a large deletion spanning multiple exons of IL2RA. The multi-exon deletion c.557_795-1625del identified in patient 2 represents, to our knowledge, the first reported structural null allele of IL2RA. This deletion results in the complete loss of several essential exons, accounting for the observed absence of CD25 expression. Its identification highlights the importance of actively investigating copy number variations in patients with IPEX-like phenotypes, particularly when conventional sequencing fails to detect point mutations. This finding underscores the role of multi-exon deletions as an underlying genetic mechanism of IL2RA deficiency and enhances our understanding of CD25 loss in these patients. Large deletions can be challenging to detect by standard gene panel sequencing, but in our targeted NGS approach we were able to infer the deletion from read-depth analysis. These two mutations underscore that IL2RA pathogenic variants can be diverse (point mutations, indels, splice defects, large deletions), and comprehensive genetic testing is often required to identify them.

Clinically, both patients reinforce certain patterns noted in CD25 deficiency. First, the onset of disease is in early infancy. Patient 1 and patient 2 both showed symptoms within the first year of life. This is consistent with the notion that IL-2Rα is critical from the neonatal period for immune regulation. Second, consanguinity was present in both families. Given the autosomal recessive inheritance, CD25 deficiency is more likely to appear in settings of parental consanguinity or endogamous communities. This is an important epidemiological clue; indeed, most previously reported cases were from consanguineous families, including reports from communities in the Middle East and South Asia (16, 17). Our report highlights that this disorder, while exceedingly rare, can also occur in North Africa, and underscores the need to consider IL2RA mutations in patients from this region presenting with IPEX-like features. Third, while both our patients had multiple autoimmune diseases, the exact spectrum can vary. Case 1 had severe autoimmune hepatitis, whereas Case 2 had autoimmune thyroiditis. In the literature, autoimmune enteropathy is the most common feature (16), and both of our patients indeed had enteropathy, with biopsy-proven celiac-like disease. Other reported autoimmune manifestations include type 1 diabetes mellitus, which can be an early presenting feature in up to ~60% of cases, autoimmune skin conditions (eczema or psoriasis), and autoimmune cytopenias (11, 16, 27, 28). Neither of our patients has developed diabetes to date, although they remain at risk given the breakdown of tolerance (regular monitoring is in place). Unlike FOXP3 deficiency, IL2RA deficiency does not involve mutations in FOXP3 but results from impaired IL-2 signaling required to sustain FOXP3 expression in Tregs (11, 12, 16). Despite some clinical differences, including occasionally more pronounced lymphoproliferation, the strong phenotypic overlap supports classifying CD25 deficiency among IPEX-like syndromes, alongside STAT5b, CTLA4, and LRBA deficiencies (17). Although hyperleukocytosis and elevated IgG levels were observed in both patients, these findings alone do not constitute a specific biological profile that would allow a definitive diagnosis of CD25 deficiency. In contrast, the absence of CD25⁺ cells represents the key element in the diagnostic reasoning.

From a management standpoint, the definitive treatment for CD25 deficiency is hematopoietic stem cell transplantation (HSCT). Restoring a functional immune system via HSCT, ideally from an HLA-matched sibling or suitable donor, has been shown to cure the immune dysregulation in at least one reported case (16). Al-Sukaiti et al. documented an infant with CD25 deficiency who underwent a successful bone marrow transplant, resulting in resolution of his autoimmune diabetes and other manifestations (16). HSCT provides donor-derived T cells that express CD25, thereby re-establishing IL-2 responsive regulatory T cells and normalizing immune homeostasis. Both of our patients are being evaluated for potential HSCT while receiving supportive therapy. In the interim, meticulous multidisciplinary care is required: management includes aggressive treatment of infections (prophylactic antibiotics, antifungals and antivirals as needed) and immunosuppressive therapy to control autoimmunity, for example, Case 2’s hypothyroidism is managed with hormone replacement and her enteropathy with immunosuppressants. The use of therapies like rapamycin (sirolimus) that expand regulatory T cells by exploiting IL-2 signaling could be considered, although paradoxically in CD25 deficiency the Tregs cannot respond normally to IL-2 (27). Low-dose IL-2 therapy, which has shown promise in boosting Tregs in some autoimmune conditions (29), would presumably be ineffective in CD25 absence. Therefore, immune reconstitution by transplantation remains the only curative option. Early diagnosis is essential to enable timely HSCT before irreversible organ damage from ongoing autoimmunity. Our cases highlight that CD25 deficiency should be considered in infants with unexplained multisystem autoimmunity particularly enteropathy and endocrinopathy associated with recurrent infections, especially in the context of consanguinity or affected siblings. Flow cytometric assessment of CD25 expression on T cells provides a simple initial screening tool.

These two Moroccan cases expand the geographic and genetic spectrum of IL2RA deficiency. They are, to the best of our knowledge, the first reported patients from Morocco. Prior to this, fewer than 20 cases had been recorded globally, with the largest series noting only about eight families worldwide as of a few years ago (17). Our report adds novel mutations to the literature, including a unique large deletion, and reinforces the genotype-phenotype correlation that any null mutation in IL2RA will lead to the characteristic severe autoimmune immunodeficiency syndrome. The rarity of CD25 deficiency means it is often not immediately recognized. Many patients, like the brother of Case 2, may succumb before a diagnosis is made. Increasing awareness among immunologists and pediatricians is therefore vital. In settings where infantile IPEX-like symptoms are present but FOXP3 is normal (or the patient is female, ruling out X-linked IPEX), testing for IL2RA mutations is indicated.

This study has some limitations that should be acknowledged. First, it is based on two patients from a single center, which does not allow firm conclusions about the prevalence, full phenotypic spectrum or long-term prognosis of IL2RA deficiency, particularly in North African populations. Second, although we documented a complete absence of CD25 surface expression and used several in silico tools to support the pathogenicity of the identified variants, we did not perform functional assays of IL-2 signaling (such as STAT5 phosphorylation or regulatory T-cell suppressive function) or transcript-level studies to directly confirm the splicing consequences of the c.65-2A>G variant and the impact of the multi-exon deletion at RNA and protein level. Third, genetic testing was restricted to the two index cases, and we were therefore unable to formally confirm carrier status in all relatives or to document the molecular defect in the deceased sibling of Case 2. Finally, follow-up remains relatively short, especially for the younger child, so later-onset complications cannot be excluded. These limitations do not weaken the diagnostic attribution of IL-2Rα deficiency in our patients, but they highlight the need for additional functional work and longitudinal data in larger cohorts.

5 Conclusion

We report the first two molecularly confirmed cases of IL2RA (CD25) deficiency in Morocco, each due to a novel homozygous variant, including a previously undescribed multi-exonic deletion. Both children developed disease in early life with recurrent infections, severe enteropathy and multi-organ autoimmunity, giving an IPEX-like picture typical of complete CD25 loss. The combination of absent CD25 expression on CD4⁺ T cells and biallelic IL2RA variants allowed a precise diagnosis in both cases. These observations extend the geographic and genetic spectrum of IL2RA deficiency and underline that this disorder should be considered in infants and children from consanguineous families who present with unexplained polyautoimmunity and infections, even outside previously described populations. Simple flow cytometric assessment of CD25 on T cells provides a rapid and accessible screening tool, while early genetic confirmation is essential to guide timely hematopoietic stem cell transplantation and genetic counselling. Larger collaborative series with detailed functional studies will be needed to refine genotype–phenotype correlations and to optimize management strategies for this ultra-rare but life-threatening inborn error of immunity.

Data availability statement

Datasets are available on request: The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Ethics Committee of the Ibn Rochd University Hospital Center of Casablanca under approval number 06/2023. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

Author contributions

AhE: Conceptualization, Writing – review & editing, Investigation, Project administration, Formal Analysis, Methodology, Software, Data curation, Writing – original draft. IB: Project administration, Resources, Validation, Writing – review & editing, Conceptualization, Methodology. AbE: Data curation, Methodology, Software, Formal Analysis, Writing – review & editing. YB: Methodology, Writing – original draft, Investigation, Resources. ZA: Methodology, Writing – original draft, Investigation, Formal Analysis, Resources. MF: Data curation, Investigation, Methodology, Writing – review & editing, Formal Analysis. AB: Writing – review & editing, Project administration, Resources, Methodology, Visualization, Conceptualization, Investigation, Validation, Supervision, Funding acquisition. JB: Methodology, Supervision, Conceptualization, Validation, Investigation, Data curation, Funding acquisition, Writing – review & editing, Writing – original draft, Project administration, Visualization. FA: Methodology, Validation, Conceptualization, Project administration, Supervision, Investigation, Data curation, Writing – review & editing, Writing – original draft, Visualization, Resources.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Acknowledgments

The authors would like to acknowledge the valuable contributions of JB and FA to the conception, supervision, and data collection of this study. This work was supported by the Laboratory of Clinical Immunology, Infection, and Autoimmunity (LICIA), Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.

Conflict of interest

The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2026.1753561/full#supplementary-material

References

1. Malek TR and Bayer AL. Tolerance, not immunity, crucially depends on il-2. Nat Rev Immunol. (2004) 4:665–74. doi: 10.1038/nri1435

PubMed Abstract | Crossref Full Text | Google Scholar

2. Bachmann MF and Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. (2007) 8:1142–8. doi: 10.1038/sj.embor.7401099

PubMed Abstract | Crossref Full Text | Google Scholar

3. Létourneau S, Krieg C, Pantaleo G, and Boyman O. Il-2- and cd25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol. (2009) 123:758–62. doi: 10.1016/j.jaci.2009.02.011

PubMed Abstract | Crossref Full Text | Google Scholar

4. Rochman Y, Spolski R, and Leonard WJ. New insights into the regulation of T cells by gamma(C) family cytokines. Nat Rev Immunol. (2009) 9:480–90. doi: 10.1038/nri2580

PubMed Abstract | Crossref Full Text | Google Scholar

5. Permanyer M, Bošnjak B, Glage S, Friedrichsen M, Floess S, Huehn J, et al. Efficient il-2r signaling differentially affects the stability, function, and composition of the regulatory T-cell pool. Cell Mol Immunol. (2021) 18:398–414. doi: 10.1038/s41423-020-00599-z

PubMed Abstract | Crossref Full Text | Google Scholar

6. Malek TR and Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. (2010) 33:153–65. doi: 10.1016/j.immuni.2010.08.004

PubMed Abstract | Crossref Full Text | Google Scholar

7. Caldirola MS, Rodriguez Broggi MG, Gaillard MI, Bezrodnik L, and Zwirner NW. Primary immunodeficiencies unravel the role of il-2/cd25/stat5b in human natural killer cell maturation. Front Immunol. (2018) 9:1429. doi: 10.3389/fimmu.2018.01429

PubMed Abstract | Crossref Full Text | Google Scholar

8. Hirakawa M, Matos TR, Liu H, Koreth J, Kim HT, Paul NE, et al. Low-dose il-2 selectively activates subsets of cd4(+) tregs and nk cells. JCI Insight. (2016) 1:e89278. doi: 10.1172/jci.insight.89278

PubMed Abstract | Crossref Full Text | Google Scholar

9. Bousfiha AA, Jeddane L, Moundir A, Poli MC, Aksentijevich I, Cunningham-Rundles C, et al. The 2024 update of iuis phenotypic classification of human inborn errors of immunity. J Hum Immun. (2025) 1:482–7. doi: 10.70962/jhi.20250002

PubMed Abstract | Crossref Full Text | Google Scholar

10. Sharfe N, Dadi HK, Shahar M, and Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci U.S.A. (1997) 94:3168–71. doi: 10.1073/pnas.94.7.3168

PubMed Abstract | Crossref Full Text | Google Scholar

11. Caudy AA, Reddy ST, Chatila T, Atkinson JP, and Verbsky JW. Cd25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective il-10 expression from cd4 lymphocytes. J Allergy Clin Immunol. (2007) 119:482–7. doi: 10.1016/j.jaci.2006.10.007

PubMed Abstract | Crossref Full Text | Google Scholar

12. Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, et al. Human il2ra null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol. (2013) 146:248–61. doi: 10.1016/j.clim.2013.01.004

PubMed Abstract | Crossref Full Text | Google Scholar

13. Alaifan MA, Abusharifah O, Bokhary RY, Banaganapalli B, Shaik NA, Kamal NM, et al. Granulomatous hepatitis in a saudi child with il2ra defect: A case report and literature review. Ther Adv chronic Dis. (2022) 13:20406223221116798. doi: 10.1177/20406223221116798

PubMed Abstract | Crossref Full Text | Google Scholar

14. Waheed N, Naseer M, Haider N, Suleman S, and Ullah A. Whole exome sequencing identified a novel splice donor site variant in interleukin 2 receptor alpha chain. Immunogenetics. (2023) 75:71–9. doi: 10.1007/s00251-022-01278-1

PubMed Abstract | Crossref Full Text | Google Scholar

15. Bezrodnik L, Caldirola MS, Seminario AG, Moreira I, and Gaillard MI. Follicular bronchiolitis as phenotype associated with cd25 deficiency. Clin Exp Immunol. (2014) 175:227–34. doi: 10.1111/cei.12214

PubMed Abstract | Crossref Full Text | Google Scholar

16. Sukaiti NA, Sinani AA, Ismaily SA, Shaikh S, and Abrawi SA. Pulmonary hemorrhage in a case of cd25 deficiency. LymphoSign J. (2014) 01:39–43. doi: 10.14785/lpsn-2014-0003

Crossref Full Text | Google Scholar

17. Vignoli M, Ciullini Mannurita S, Fioravanti A, Tumino M, Grassi A, Guariso G, et al. Cd25 deficiency: A new conformational mutation prevents the receptor expression on cell surface. Clin Immunol. (2019) 201:15–9. doi: 10.1016/j.clim.2019.02.003

PubMed Abstract | Crossref Full Text | Google Scholar

18. Baş Z, Bayraktutar BN, and Uçakhan Ö. Severe dry eye in cd25 deficiency syndrome. Eye contact lens. (2018) 44:e1–3. doi: 10.1097/icl.0000000000000346

PubMed Abstract | Crossref Full Text | Google Scholar

19. Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, et al. Cell-specific protein phenotypes for the autoimmune locus il2ra using a genotype-selectable human bioresource. Nat Genet. (2009) 41:1011–5. doi: 10.1038/ng.434

PubMed Abstract | Crossref Full Text | Google Scholar

20. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. New Engl J Med. (2008) 359:2767–77. doi: 10.1056/NEJMoa0807917

PubMed Abstract | Crossref Full Text | Google Scholar

21. Alcina A, Fedetz M, Ndagire D, Fernández O, Leyva L, Guerrero M, et al. Il2ra/cd25 gene polymorphisms: uneven association with multiple sclerosis (Ms) and type 1 diabetes (T1d). PloS One. (2009) 4:e4137. doi: 10.1371/journal.pone.0004137

PubMed Abstract | Crossref Full Text | Google Scholar

22. Hinks A, Ke X, Barton A, Eyre S, Bowes J, Worthington J, et al. Association of the il2ra/cd25 gene with juvenile idiopathic arthritis. Arthritis rheumatism. (2009) 60:251–7. doi: 10.1002/art.24187

PubMed Abstract | Crossref Full Text | Google Scholar

23. Garg G, Tyler JR, Yang JH, Cutler AJ, Downes K, Pekalski M, et al. Type 1 diabetes-associated il2ra variation lowers il-2 signaling and contributes to diminished cd4+Cd25+ Regulatory T cell function. J Immunol. (2012) 188:4644–53. doi: 10.4049/jimmunol.1100272

PubMed Abstract | Crossref Full Text | Google Scholar

24. Bohn MK, Wilson S, Steele S, and Adeli K. Comprehensive pediatric reference intervals for 79 hematology markers in the caliper cohort of healthy children and adolescents using the mindray bc-6800plus system. Int J Lab Hematol. (2023) 45:469–80. doi: 10.1111/ijlh.14068

PubMed Abstract | Crossref Full Text | Google Scholar

25. Jeddane L, Ouair H, Benhsaien I, Bakkouri JE, and Bousfiha AA. Primary immunodeficiency classification on smartphone. J Clin Immunol. (2017) 37:1–2. doi: 10.1007/s10875-016-0354-6

PubMed Abstract | Crossref Full Text | Google Scholar

26. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the pediatric aids clinical trials group P1009 study. J Allergy Clin Immunol. (2003) 112:973–80. doi: 10.1016/j.jaci.2003.07.003

PubMed Abstract | Crossref Full Text | Google Scholar

27. Lai N, Liu L, Lin L, Cui C, Wang Y, Min Q, et al. Effective and safe treatment of a novel il2ra deficiency with rapamycin. J Allergy Clin Immunol Pract. (2020) 8:1132–5.e4. doi: 10.1016/j.jaip.2019.09.027

PubMed Abstract | Crossref Full Text | Google Scholar

28. Korula S, Ravichandran L, Paul PG, Johnson J, Chapla A, Santhanam S, et al. Genetic heterogeneity and challenges in the management of permanent neonatal diabetes mellitus: A single-centre study from south India. Indian J Endocrinol Metab. (2022) 26:79–86. doi: 10.4103/ijem.ijem_429_21

PubMed Abstract | Crossref Full Text | Google Scholar

29. Graßhoff H, Comdühr S, Monne LR, Müller A, Lamprecht P, Riemekasten G, et al. Low-dose il-2 therapy in autoimmune and rheumatic diseases. Front Immunol. (2021) 12:648408. doi: 10.3389/fimmu.2021.648408

PubMed Abstract | Crossref Full Text | Google Scholar

30. Goncalves DG, Cau LP, Salles PD, Marques PQ, Lopes MM, Yonekura Anagusko CL, et al. Another case of interleukin-2 receptor alpha chain (Il2ra) deficiency. J Allergy Clin Immunol. (2017) 139:AB17. doi: 10.1016/j.jaci.2016.12.011

Crossref Full Text | Google Scholar